TW202045170A - 一種含有腎臟鉀離子外排通道抑制劑的藥物組合物及其製備方法 - Google Patents

一種含有腎臟鉀離子外排通道抑制劑的藥物組合物及其製備方法 Download PDF

Info

Publication number: TW202045170A
Authority: TW; Taiwan
Prior art keywords: pharmaceutical composition; content; impurity; composition according; total weight
Prior art date: 2019-02-28

Application number

TW109106365A

Other languages

English (en)

Chinese (zh)

Inventor

奚宏磊

Original Assignee

大陸商江蘇恒瑞醫藥股份有限公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-02-28

Filing date

2020-02-27

Publication date

2020-12-16

2020-02-27 Application filed by 大陸商江蘇恒瑞醫藥股份有限公司 filed Critical 大陸商江蘇恒瑞醫藥股份有限公司

2020-12-16 Publication of TW202045170A publication Critical patent/TW202045170A/zh

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 69
239000003112 inhibitor Substances 0.000 title abstract description 6
229910001414 potassium ion Inorganic materials 0.000 title abstract description 5
238000004519 manufacturing process Methods 0.000 title abstract description 4
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 title abstract description 3
150000003839 salts Chemical class 0.000 claims abstract description 17
239000000203 mixture Substances 0.000 claims description 65
239000012535 impurity Substances 0.000 claims description 38
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 claims description 27
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 26
239000008101 lactose Substances 0.000 claims description 22
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 14
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 14
235000019359 magnesium stearate Nutrition 0.000 claims description 14
229920002785 Croscarmellose sodium Polymers 0.000 claims description 13
229960001681 croscarmellose sodium Drugs 0.000 claims description 13
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 13
239000000546 pharmaceutical excipient Substances 0.000 claims description 13
229940124531 pharmaceutical excipient Drugs 0.000 claims description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
239000011248 coating agent Substances 0.000 claims description 12
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
239000000377 silicon dioxide Substances 0.000 claims description 12
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
239000007884 disintegrant Substances 0.000 claims description 11
239000008187 granular material Substances 0.000 claims description 11
239000000314 lubricant Substances 0.000 claims description 11
239000000945 filler Substances 0.000 claims description 10
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
239000013543 active substance Substances 0.000 claims description 9
-1 glidants Substances 0.000 claims description 9
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
239000008108 microcrystalline cellulose Substances 0.000 claims description 9
229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
229960001866 silicon dioxide Drugs 0.000 claims description 9
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 8
239000011149 active material Substances 0.000 claims description 8
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
239000004372 Polyvinyl alcohol Substances 0.000 claims description 7
238000000576 coating method Methods 0.000 claims description 7
239000000463 material Substances 0.000 claims description 7
229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
235000012239 silicon dioxide Nutrition 0.000 claims description 7
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
238000001514 detection method Methods 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
239000011734 sodium Substances 0.000 claims description 6
239000000454 talc Substances 0.000 claims description 6
229910052623 talc Inorganic materials 0.000 claims description 6
235000012222 talc Nutrition 0.000 claims description 6
239000001856 Ethyl cellulose Substances 0.000 claims description 5
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
239000002202 Polyethylene glycol Substances 0.000 claims description 5
239000002775 capsule Substances 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
235000019325 ethyl cellulose Nutrition 0.000 claims description 5
229920001249 ethyl cellulose Polymers 0.000 claims description 5
229960003943 hypromellose Drugs 0.000 claims description 5
238000000034 method Methods 0.000 claims description 5
229920001223 polyethylene glycol Polymers 0.000 claims description 5
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 4
238000007907 direct compression Methods 0.000 claims description 4
238000007908 dry granulation Methods 0.000 claims description 4
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
230000014759 maintenance of location Effects 0.000 claims description 4
229940049920 malate Drugs 0.000 claims description 4
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
239000003826 tablet Substances 0.000 claims description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
206010019280 Heart failures Diseases 0.000 claims description 3
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
229920002472 Starch Polymers 0.000 claims description 3
229920000609 methyl cellulose Polymers 0.000 claims description 3
239000001923 methylcellulose Substances 0.000 claims description 3
235000010981 methylcellulose Nutrition 0.000 claims description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
239000002245 particle Substances 0.000 claims description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
229940069328 povidone Drugs 0.000 claims description 3
239000000843 powder Substances 0.000 claims description 3
229940083542 sodium Drugs 0.000 claims description 3
239000008107 starch Substances 0.000 claims description 3
235000019698 starch Nutrition 0.000 claims description 3
238000005550 wet granulation Methods 0.000 claims description 3
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 2
QGQXAMBOYWULFX-LZWSPWQCSA-N 2-morpholin-4-ylethyl (e)-6-(4,6-dihydroxy-7-methyl-3-oxo-1h-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound OC=1C=2C(=O)OCC=2C(C)=C(O)C=1C\C=C(/C)CCC(=O)OCCN1CCOCC1 QGQXAMBOYWULFX-LZWSPWQCSA-N 0.000 claims description 2
208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
201000001320 Atherosclerosis Diseases 0.000 claims description 2
208000024172 Cardiovascular disease Diseases 0.000 claims description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
229920002261 Corn starch Polymers 0.000 claims description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
229920001353 Dextrin Polymers 0.000 claims description 2
239000004375 Dextrin Substances 0.000 claims description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
206010020852 Hypertonia Diseases 0.000 claims description 2
208000000913 Kidney Calculi Diseases 0.000 claims description 2
229930195725 Mannitol Natural products 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
229920000881 Modified starch Polymers 0.000 claims description 2
206010029148 Nephrolithiasis Diseases 0.000 claims description 2
206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
235000021314 Palmitic acid Nutrition 0.000 claims description 2
208000033626 Renal failure acute Diseases 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
235000021355 Stearic acid Nutrition 0.000 claims description 2
208000006011 Stroke Diseases 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
230000001154 acute effect Effects 0.000 claims description 2
229920003144 amino alkyl methacrylate copolymer Polymers 0.000 claims description 2
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
239000011575 calcium Substances 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
239000004203 carnauba wax Substances 0.000 claims description 2
235000013869 carnauba wax Nutrition 0.000 claims description 2
208000020832 chronic kidney disease Diseases 0.000 claims description 2
208000019425 cirrhosis of liver Diseases 0.000 claims description 2
229920001577 copolymer Polymers 0.000 claims description 2
239000008120 corn starch Substances 0.000 claims description 2
229960000913 crospovidone Drugs 0.000 claims description 2
235000019425 dextrin Nutrition 0.000 claims description 2
239000006185 dispersion Substances 0.000 claims description 2
238000010828 elution Methods 0.000 claims description 2
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
238000011049 filling Methods 0.000 claims description 2
239000008103 glucose Substances 0.000 claims description 2
229940049654 glyceryl behenate Drugs 0.000 claims description 2
239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
239000000594 mannitol Substances 0.000 claims description 2
235000010355 mannitol Nutrition 0.000 claims description 2
230000001404 mediated effect Effects 0.000 claims description 2
229910002055 micronized silica Inorganic materials 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
208000010125 myocardial infarction Diseases 0.000 claims description 2
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
229920002689 polyvinyl acetate Polymers 0.000 claims description 2
239000011118 polyvinyl acetate Substances 0.000 claims description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
208000002815 pulmonary hypertension Diseases 0.000 claims description 2
229920005989 resin Polymers 0.000 claims description 2
239000011347 resin Substances 0.000 claims description 2
239000000741 silica gel Substances 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
235000015424 sodium Nutrition 0.000 claims description 2
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
239000008117 stearic acid Substances 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
229920002554 vinyl polymer Polymers 0.000 claims description 2
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
229940077388 benzenesulfonate Drugs 0.000 claims 1
239000007853 buffer solution Substances 0.000 claims 1
235000014113 dietary fatty acids Nutrition 0.000 claims 1
239000000194 fatty acid Substances 0.000 claims 1
229930195729 fatty acid Natural products 0.000 claims 1
239000000835 fiber Substances 0.000 claims 1
229940050549 fiber Drugs 0.000 claims 1
229940050411 fumarate Drugs 0.000 claims 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
230000002685 pulmonary effect Effects 0.000 claims 1
229910052710 silicon Inorganic materials 0.000 claims 1
239000010703 silicon Substances 0.000 claims 1
238000004090 dissolution Methods 0.000 abstract description 14
HHEAGUQDCLLWMT-QFIPXVFZSA-N C(#N)C=1C(=CC(=NC=1)C(=O)NC1CCN(CC1)C[C@@H](C=1C(=C2COC(C2=CC=1)=C=O)C)O)OC Chemical compound C(#N)C=1C(=CC(=NC=1)C(=O)NC1CCN(CC1)C[C@@H](C=1C(=C2COC(C2=CC=1)=C=O)C)O)OC HHEAGUQDCLLWMT-QFIPXVFZSA-N 0.000 abstract 1
238000013112 stability test Methods 0.000 description 11
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
239000000523 sample Substances 0.000 description 7
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
229910052782 aluminium Inorganic materials 0.000 description 6
108091006146 Channels Proteins 0.000 description 5
206010020772 Hypertension Diseases 0.000 description 5
239000008186 active pharmaceutical agent Substances 0.000 description 5
239000002934 diuretic Substances 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
239000011230 binding agent Substances 0.000 description 4
239000011888 foil Substances 0.000 description 4
229960001375 lactose Drugs 0.000 description 4
239000004408 titanium dioxide Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
229940030606 diuretics Drugs 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000007888 film coating Substances 0.000 description 3
238000009501 film coating Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
238000005259 measurement Methods 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
239000000243 solution Substances 0.000 description 3
102100033056 ATP-sensitive inward rectifier potassium channel 1 Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
101000944272 Homo sapiens ATP-sensitive inward rectifier potassium channel 1 Proteins 0.000 description 2
208000019025 Hypokalemia Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 2
229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 2
230000001882 diuretic effect Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000001631 hypertensive effect Effects 0.000 description 2
238000005286 illumination Methods 0.000 description 2
229940057948 magnesium stearate Drugs 0.000 description 2
235000019837 monoammonium phosphate Nutrition 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
229940068918 polyethylene glycol 400 Drugs 0.000 description 2
208000024896 potassium deficiency disease Diseases 0.000 description 2
230000009103 reabsorption Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000005507 spraying Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
244000043158 Lens esculenta Species 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
229920003081 Povidone K 30 Polymers 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
MGQQZGJIMOVHRZ-UHFFFAOYSA-N [Si].O=O Chemical compound [Si].O=O MGQQZGJIMOVHRZ-UHFFFAOYSA-N 0.000 description 1
230000009102 absorption Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000010432 diamond Substances 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
230000035619 diuresis Effects 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229960004667 ethyl cellulose Drugs 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
229940075065 polyvinyl acetate Drugs 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
230000003823 potassium efflux Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000010008 shearing Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
239000000126 substance Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
230000002522 swelling effect Effects 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
WKOLLVMJNQIZCI-UHFFFAOYSA-M vanillate Chemical compound COC1=CC(C([O-])=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-M 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

TW109106365A 2019-02-28 2020-02-27 一種含有腎臟鉀離子外排通道抑制劑的藥物組合物及其製備方法 TW202045170A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN201910152541		2019-02-28
CN201910152541.9		2019-02-28

Publications (1)

Publication Number	Publication Date
TW202045170A true TW202045170A (zh)	2020-12-16

Family

ID=72238374

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW109106365A TW202045170A (zh)	2019-02-28	2020-02-27	一種含有腎臟鉀離子外排通道抑制劑的藥物組合物及其製備方法

Country Status (3)

Country	Link
CN (1)	CN113226315B (fr)
TW (1)	TW202045170A (fr)
WO (1)	WO2020173476A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105980379B (zh) *	2014-12-08	2018-09-07	江苏恒瑞医药股份有限公司	吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用
MX2018014759A (es) *	2016-06-07	2019-03-11	Jiangsu Hengrui Medicine Co	Sal farmaceuticamente aceptable como inhibidor del canal de potasio medular externo renal.
CN108113988A (zh) *	2016-11-29	2018-06-05	江苏恒瑞医药股份有限公司	一种romk抑制剂与arb联合在制备治疗和/或预防高血压或心力衰竭的药物中的用途

2020
- 2020-02-27 WO PCT/CN2020/076925 patent/WO2020173476A1/fr not_active Ceased
- 2020-02-27 TW TW109106365A patent/TW202045170A/zh unknown
- 2020-02-27 CN CN202080007525.1A patent/CN113226315B/zh active Active

Also Published As

Publication number	Publication date
CN113226315B (zh)	2023-05-16
WO2020173476A1 (fr)	2020-09-03
CN113226315A (zh)	2021-08-06

Publication	Publication Date	Title
AU2019278016B2 (en)	2024-10-10	Pharmaceutical combination, composition and combination formulation comprising glucokinase activator and DPP‐IV inhibitor, and preparation method and use thereof
KR101406767B1 (ko)	2014-06-20	프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출성 정제 제형, 이의 제조방법 및 이의용도
KR102072546B1 (ko)	2020-02-04	레날리도마이드의 경구용 정제 조성물
WO2011069326A1 (fr)	2011-06-16	Comprimé bicouche comprenant de l'aténolol et de l'amlodipine
US20230346817A1 (en)	2023-11-02	Composition and use of sglt-2 inhibitor and angiotensin receptor blockers
KR20180049510A (ko)	2018-05-11	암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
WO2020109319A1 (fr)	2020-06-04	Composition pharmaceutique comprenant du ramipril et de l'indapamide
TWI414310B (zh)	2013-11-11	溶出性改善之醫藥品組成物
JP2009521526A (ja)	2009-06-04	カンシル酸アムロジピン及びシンバスタチンを含む複合製剤及びその製造方法
CN109481437B (zh)	2020-12-18	一种氯沙坦钾药物制剂
TW202045170A (zh)	2020-12-16	一種含有腎臟鉀離子外排通道抑制劑的藥物組合物及其製備方法
CN119074728A (zh)	2024-12-06	用于高血压治疗的多重释放组合物
JP2022140430A (ja)	2022-09-26	リバーロキサバン含有錠剤
CA3101831C (fr)	2025-11-25	Combinaison pharmaceutique, composition et formulation de combinaison comprenant l'activateur de glucokinase et un inhibiteur de dpp-iv et methode de preparation et d'utilisation
CA3101829C (fr)	2026-04-21	Combinaison pharmaceutique, composition et formulation de combinaison comprenant l'activateur de glucokinase et un inhibiteur de sglt-2 et methodes de preparation et d'utilisation
RU2770043C9 (ru)	2022-05-27	Фармацевтическая комбинация, композиция и комбинированная композиция, содержащая активатор глюкокиназы и ингибитор sglt-2, и способы их приготовления и их применения
CN113171352A (zh)	2021-07-27	一种沙坦类降压复方制剂的制备方法
RU2261094C1 (ru)	2005-09-27	Твердая лекарственная форма для лечения артериальной гипертензии и способ ее изготовления